IntelGenx Corp. Product Segmentation & Forecast - 2015 - PowerPoint PPT Presentation

Loading...

PPT – IntelGenx Corp. Product Segmentation & Forecast - 2015 PowerPoint presentation | free to download - id: 7ebadd-ZjNiN



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

IntelGenx Corp. Product Segmentation & Forecast - 2015

Description:

This report provides comprehensive information on the current therapeutic developmental pipeline of IntelGenx Corp. s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Enquiry @ – PowerPoint PPT presentation

Number of Views:12

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: IntelGenx Corp. Product Segmentation & Forecast - 2015


1
Intel Genx Corp.Product Pipeline Review - 2015
No. Pages 44
Published on October - 2015
2
.
Report Overview
About Intel Genx Corp. Product Pipeline Review -
2015 Global Markets Directs, Intel Genx Corp.
Product Pipeline Review - 2015, provides an
overview of the Intel Genx Corp. s,
pharmaceutical research and development focus.
This report provides comprehensive information on
the current therapeutic developmental pipeline of
Intel Genx Corp. s, complete with comparative
analysis at various stages, therapeutics
assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule
type. It also reviews latest updates, and
featured news and press releases, along with
special features on late-stage and discontinued
projects. Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Get
Full Details On http//www.researchbeam.com/inte
lgenx-corp-product-pipeline-review-2015-market

3
.
Report Overview
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease. Scope The report provides
brief overview of Five Prime Therapeutics,
Inc.including business description, key
information and facts, and its locations and
subsidiaries The report reviews current pipeline
of Five Prime Therapeutics, Inc.s human
therapeutic division and enlists all their major
and minor projects
4
.
Report Overview
The report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
Five Prime Therapeutics, Inc.s pipeline
products   Reasons to buy Evaluate Five Prime
Therapeutics, Inc.s strategic position with total
access to detailed information on its product
pipeline Assess the growth potential of Five
Prime Therapeutics, Inc.in its therapy areas of
focus Identify new drug targets and therapeutic
classes in the Five Prime Therapeutics, Inc.s RD
portfolio and develop key strategic initiatives
to reinforce pipeline in those areas Exploit
in-licensing opportunities by identifying windows
of opportunity to fill portfolio gaps
5
Report Overview
  • Develop strategic initiatives by understanding
    the focus areas of Five Prime Therapeutics,
    Inc.and exploit collaboration and partnership
    opportunities
  • Identify emerging players with potentially strong
    product portfolio and create effective
    counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by
    identifying the most promising pipeline of Five
    Prime Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope
  • Explore the dormant and discontinued projects of
    Five Prime Therapeutics, Inc.and identify
    potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

6
Table Of Contents
List of Tables 4 List of Figures 4 IntelGenx
Corp. Snapshot 5 IntelGenx Corp. Overview 5 Key
Information 5 Key Facts 5 IntelGenx Corp. -
Research and Development Overview 6 Key
Therapeutic Areas 6 IntelGenx Corp. - Pipeline
Review 8 Pipeline Products by Stage of
Development 8 Pipeline Products - Monotherapy
9 Pipeline Products - Partnered Products
10 Partnered Products/Combination Treatment
Modalities 11 Pipeline Products - Out-Licensed
Products 12
7
Table Of Contents
Out-Licensed Products/Combination Treatment
Modalities 13 IntelGenx Corp. - Pipeline Products
Glance 14 IntelGenx Corp. - Clinical Stage
Pipeline Products 14 Phase I Products/Combination
Treatment Modalities 14 IntelGenx Corp. - Early
Stage Pipeline Products 15 Preclinical
Products/Combination Treatment Modalities
15 Discovery Products/Combination Treatment
Modalities 16 IntelGenx Corp. - Drug Profiles
17 INT-0028 17 Product Description 17 Mechanism
of Action 17 RD Progress 17 INT-0036 18 Product
Description 18
8
Table Of Contents
Mechanism of Action 18 RD Progress 18 metoprolol
succinate 19 Product Description 19 Mechanism of
Action 19 RD Progress 19 tadalafil 20 Product
Description 20 Mechanism of Action 20 RD
Progress 20 INT-0031 21 Product Description
21 Enquiry about this report _at_ http//www.research
beam.com/intelgenx-corp-product-pipeline-review-20
15-market/enquire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/intelgenx-corp-product
-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 E-MAIL
sales_at_researchbeam.com
About PowerShow.com